GlassScriptPhysician profile
Caitlin M Mcdaniel
NPI 1902432842
$1,543.69
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $43.54 · 2023: $568 · 2024: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.52 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $195.44 | 2023-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $134.22 | 2023-2024 | Mounjaro, Zepbound |
| Corium, LLC | $125.26 | 2023-2024 | Azstarys |
| Astellas Pharma US INC | $98.21 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $71.07 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $70.55 | 2023-2024 | Verquvo, Belsomra |
| Pfizer INC. | $69.38 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.64 | 2024 | Trulance |
| Amgen INC. | $57.74 | 2023-2024 | Otezla, Repatha, Prolia |
| Sumitomo Pharma America, INC. | $48.90 | 2024 | Gemtesa, Myfembree |
| Glaxosmithkline, LLC. | $48.30 | 2022-2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $32.89 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $31.81 | 2023 | |
| Lundbeck LLC | $30.04 | 2023 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $23.72 | 2024 | |
| Axsome Therapeutics, INC. | $23.12 | 2023 | Sunosi |
| Tolmar, INC. | $22.36 | 2024 | |
| Noven Therapeutics, LLC | $20.24 | 2023 | Xelstrym |
| Novartis Pharmaceuticals Corporation | $19.46 | 2022 | |
| Antares Pharma, INC. | $18.68 | 2024 | Xyosted |
| Eisai INC. | $18.56 | 2023 | |
| Currax Pharmaceuticals LLC | $13.38 | 2024 | Contrave, Onzetra Xsail |
| Dynavax Technologies Corporation | $11.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.